Salipro Biotech inks collaboration and license agreement with AbCellera

Stockholm, SwedenWednesday, October 13, 2021, 12:00 Hrs  [IST]

Swedish biotech company Salipro Biotech AB announced that it has entered into a collaboration and licensing agreement with AbCellera for access to its proprietary Salipro Platform, which stabilizes challenging G protein coupled receptor (GPCR), ion channel, and transporter antigens.

“We are excited to build on the success of our previous studies and deepen our relationship with the team at AbCellera,” said Jens Frauenfeld, CEO of Salipro Biotech. “We look forward to deploying our expertise and our platform technology to generate Salipro-stabilized antigens of challenging membrane proteins to enable AbCellera’s discovery programs against these drug targets.”

Under the terms of the agreement, Salipro Biotech will receive an upfront payment, research payments and is eligible for downstream milestone payments for a defined number of targets.

Salipro Biotech AB is a privately held biotech company focused on unlocking challenging drug targets for the development of next-generation therapeutics.